Home
Products
Learn
About
Pricing
Log In

What are you looking for?

Home
Pricing
Compare AU

Compare RIIF vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Resolution Gbl Listed Infra Fund - Active ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are RIIF and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

RIIF

CURE

Popularity

N/A

Low

Pearlers invested

0

77

Median incremental investment

$0

$640.11

Median investment frequency

N/A

Monthly

Median total investment

$0

$1,181.75

Average age group

N/A

> 35


Key Summary

RIIF

CURE

Strategy

RIIF.AX was created on 2024-08-12 by Resolution Capital. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to achieve an annual total return that exceeds the total return of the Benchmark after fees on a rolling 3-year basis

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Resolution Gbl Listed Infra Fund - Active ETF (100 %)

Natera Inc (2.88 %)

Vertex Pharmaceuticals Inc (2.77 %)

Insmed Inc (2.63 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0 %

0.45 %


Key Summary

RIIF

CURE

Issuer

Resolution Capital

Global X

Tracking index

FTSE Developed Core Infrastructure 50/50 Index - AUD - Benchmark TR Net Hedged

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0 %

0.45 %

Price

$1.085

$40.75

Size

N/A

$28.786 million

10Y return

N/A

N/A

Annual dividend/ distribution yield (5Y)

0.17 %

4.24 %

Market

ASX

ASX

First listed date

24/03/2025

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

RIIF

CURE

Popularity

N/A

Low

Pearlers invested

0

77

Median incremental investment

$0

$640.11

Median investment frequency

N/A

Monthly

Median total investment

$0

$1,181.75

Average age group

N/A

> 35


Pros and Cons

RIIF

CURE

Pros

  • Lower management fee

  • Higher price growth

  • Higher exposure to US market

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower distribution yield

  • Higher management fee

  • Lower price growth

RIIF

CURE

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield